Please login to the form below

Not currently logged in
Email:
Password:

peptide

This page shows the latest peptide news and features for those working in and with pharma, biotech and healthcare.

Amgen and Novartis migraine drug hits the mark again

Amgen and Novartis migraine drug hits the mark again

treatments. The drug - which is vying to become the first calcitonin gene-related peptide (CGRP) receptor-targeting drug to reach the market for migraine - was more than twice as likely to

Latest news

More from news
Approximately 0 fully matching, plus 132 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... licence agreement in January with respect to calcitonin gene-related peptide

  • Gene therapy Gene therapy

    Finally, looking beyond liposome versus viral delivery, alternative technologies such as new polymers, conjugates, vesicles, dendrimers and peptide nanoparticles, such as LipTide (an ‘artificial virus’), urgently need investment and further

  • Deal Watch - May 2017 Deal Watch - May 2017

    An example is the deal between Janssen and the Japanese company Peptidream that has a peptide discovery platform. ... The most advanced is an immuno-oncology peptide in phase 1 partnered with BMS.

  • Deal Watch February 2017 Deal Watch February 2017

    Acquisition - company. 705. Advaxis/ SELLAS Life Sciences Group. Advaxis' Lm-based antigen delivery technology with SELLAS’WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S) (pre-clinical).

  • Deal Watch December 2016 Deal Watch December 2016

    The size of the deals signed by AstraZeneca with Bicycle Therapeutics, by Spark with Selecta Biosciences and by Celgene with Evotec suggest that their technologies (Bicycle's bicyclic peptides, which combine

More from intelligence
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • JPT Peptide Technologies

    JPT Peptide Technologies. We are a one of the largest custom peptide vendors worldwide. ... such as custom peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptides with post-translational modifications, fluorescence labels,

  • Sales

    Creative peptides is specialized in the process development and the manufacturing of bioactive peptides. ... We offer custom peptide synthesis, process development, GMP manufacturing as well as catalog products.

  • Research and development

    We are a one of the largest custom peptide vendors worldwide. ... such as custom peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptides with post-translational modifications, fluorescence labels, biotin or other

  • Creative Peptides

    Creative Peptides. Creative peptides is specialized in the process development and the manufacturing of bioactive peptides. ... We offer custom peptide synthesis, process development, GMP manufacturing as well as catalog products.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics